JP5412430B2 - ｍＧｌｕ５拮抗薬としての新規複素環系化合物 - Google Patents

ｍＧｌｕ５拮抗薬としての新規複素環系化合物 Download PDF

Info

Publication number
JP5412430B2
JP5412430B2 JP2010518567A JP2010518567A JP5412430B2 JP 5412430 B2 JP5412430 B2 JP 5412430B2 JP 2010518567 A JP2010518567 A JP 2010518567A JP 2010518567 A JP2010518567 A JP 2010518567A JP 5412430 B2 JP5412430 B2 JP 5412430B2
Authority
JP
Japan
Prior art keywords
pyridyl
piperidine
prop
methyl
ynylidene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010518567A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010535165A5 (https=
JP2010535165A (ja
Inventor
レオナルディ，アメデオ
モッタ，ジャンニ
リヴァ，カルロ
ポッゲシ，エレナ
グラツィアーニ，ダヴィデ
マルコ ロンギー，マッテオ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Recordati Ireland Ltd
Original Assignee
Recordati Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Recordati Ireland Ltd filed Critical Recordati Ireland Ltd
Publication of JP2010535165A publication Critical patent/JP2010535165A/ja
Publication of JP2010535165A5 publication Critical patent/JP2010535165A5/ja
Application granted granted Critical
Publication of JP5412430B2 publication Critical patent/JP5412430B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2010518567A 2007-08-02 2008-08-01 ｍＧｌｕ５拮抗薬としての新規複素環系化合物 Expired - Fee Related JP5412430B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US95367707P 2007-08-02 2007-08-02
US60/953,677 2007-08-02
US4517508P 2008-04-15 2008-04-15
US61/045,175 2008-04-15
PCT/EP2008/006351 WO2009015897A1 (en) 2007-08-02 2008-08-01 Novel heterocyclic compounds as mglu5 antagonists

Publications (3)

Publication Number Publication Date
JP2010535165A JP2010535165A (ja) 2010-11-18
JP2010535165A5 JP2010535165A5 (https=) 2012-01-12
JP5412430B2 true JP5412430B2 (ja) 2014-02-12

Family

ID=39885225

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010518567A Expired - Fee Related JP5412430B2 (ja) 2007-08-02 2008-08-01 ｍＧｌｕ５拮抗薬としての新規複素環系化合物

Country Status (22)

Country Link
US (1) US8518916B2 (https=)
EP (1) EP2178858B1 (https=)
JP (1) JP5412430B2 (https=)
KR (1) KR20100052507A (https=)
CN (1) CN101821256A (https=)
AT (1) ATE539075T1 (https=)
AU (1) AU2008282032B2 (https=)
BR (1) BRPI0814182A2 (https=)
CA (1) CA2694359A1 (https=)
CY (1) CY1112500T1 (https=)
DK (1) DK2178858T3 (https=)
EA (1) EA018328B1 (https=)
ES (1) ES2380165T3 (https=)
HR (1) HRP20120225T1 (https=)
IL (1) IL203659A (https=)
NZ (1) NZ582934A (https=)
PL (1) PL2178858T3 (https=)
PT (1) PT2178858E (https=)
RS (1) RS52167B (https=)
SI (1) SI2178858T1 (https=)
WO (1) WO2009015897A1 (https=)
ZA (1) ZA201001467B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010089119A1 (en) * 2009-02-04 2010-08-12 Recordati Ireland Limited Heterocyclic derivatives as m-glu5 antagonists
US20120028931A1 (en) * 2009-09-14 2012-02-02 Recordati Ireland Limited Heterocyclic m-glu5 antagonists
WO2012085166A1 (en) * 2010-12-22 2012-06-28 Merz Pharma Gmbh & Co. Kgaa Metabotropic glutamate receptor modulators
AR084515A1 (es) * 2010-12-22 2013-05-22 Merz Pharma Gmbh & Co Kgaa Derivados heterociclicos nitrogenados, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades asociadas al sistema nervioso central tales como parkinson y alzheimer, entre otras
CN104011016B (zh) * 2011-12-27 2016-08-17 帝斯曼知识产权资产管理有限公司 维生素a中间体的催化合成
CN102827056B (zh) * 2012-09-03 2014-07-23 华东理工大学 N-芳基取代吡咯烷酮衍生物及其用途
WO2014039049A1 (en) * 2012-09-07 2014-03-13 Empire Technology Development Llc Regioregular copolymers and methods for making same
AU2014211727B2 (en) * 2013-02-04 2018-07-26 Prexton Therapeutics Sa Positive allosteric modulators of mGluR3
CA3066193A1 (en) * 2017-06-29 2019-01-03 Recordati Industria Chimica E Farmaceutica Spa Heterocyclylmethylidene derivatives and their use as modulators of mglur5 receptors

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE24826E (en) * 1956-08-30 1960-05-17 N-alkylpiperidyl alkynylamines
JPS5995249A (ja) * 1982-11-24 1984-06-01 Ono Pharmaceut Co Ltd ロイコトリエンｂ４類似化合物、その製造方法及びそれらを有効成分として含有する治療剤
EP0537993A1 (en) * 1991-10-17 1993-04-21 Eli Lilly And Company Nicotinic activity of a series of arecolones and isoarecolones
US5990114A (en) * 1996-02-28 1999-11-23 Recordati, S.A., Chemical And Pharmaceutical Company Use of 5-HT1A receptor antagonists for the treatment of urinary incontinence
AP2005003199A0 (en) * 1999-04-01 2005-03-31 Pfizer Prod Inc Aminopyrimidines as sorbitol dehydrogenase inhibitors
US6265434B1 (en) * 1999-04-06 2001-07-24 Merck & Co., Inc. Pyrrolidine modulators of chemokine receptor activity
TW593241B (en) 1999-04-20 2004-06-21 Hoffmann La Roche Carbamic acid derivatives
ITMI991452A1 (it) * 1999-07-01 2001-01-01 Mediolanum Farmaceutici Srl Antagonisti selettivi per i recettori m2 con struttura 5h-dibenzo b,fazepinica
US6387909B1 (en) * 1999-07-30 2002-05-14 Recordati S.A. Chemical And Pharmaceutical Company Thienopyranecarboxamide derivatives
US6306861B1 (en) * 1999-07-30 2001-10-23 Recordati S.A. Chemical And Pharmaceutical Company Thienopyrancecarboxamide derivatives
US6548522B1 (en) 1999-10-12 2003-04-15 Hoffmann-La Roche Inc. Method for treating conditions related to the glutamate receptor using carboxylic acid amide derivatives
US6403594B1 (en) * 1999-10-18 2002-06-11 Recordati, S.A. Chemical And Pharmaceutical Company Benzopyran derivatives
US6365591B1 (en) * 1999-10-18 2002-04-02 Recordati, S.A., Chemical And Pharmacueticals Company Isoxazolecarboxamide derivatives
EP1230225A2 (en) 1999-11-01 2002-08-14 Eli Lilly And Company Pharmaceutically active 4-substituted pyrimidine derivatives
ATE273695T1 (de) 2000-06-28 2004-09-15 Smithkline Beecham Plc Nassvermahlung
US6369222B1 (en) * 2000-07-18 2002-04-09 Hoffmann-La Roche Inc. mGluR antagonists and a method for their synthesis
WO2003093236A1 (en) * 2002-05-02 2003-11-13 Euro-Celtique, S.A. 1-(pyrid-2-yl)-piperazine compounds as metabotropic glutamate receptor inhibitor
US7348337B2 (en) * 2002-05-28 2008-03-25 Bristol-Myers Squibb Company Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides
DK1539739T3 (da) * 2002-08-16 2011-03-07 Janssen Pharmaceutica Nv Piperidinylforbindelser, der selektivt binder integriner
WO2004041777A2 (en) 2002-10-30 2004-05-21 Merck & Co., Inc. Heteroarylpiperidine modulators of chemokine receptor activity
US7572922B2 (en) * 2003-01-27 2009-08-11 Merck & Co., Inc. Substituted pyrazoles, compositions containing such compounds and methods of use
ITMI20030151A1 (it) * 2003-01-30 2004-07-31 Recordati Ind Chimica E Farma Ceutica S P A Uso di antagonisti selettivi del recettore mglu5 per il trattamento di disfunzioni neuromuscolari del tratto urinario inferiore.
US7338954B2 (en) * 2003-09-17 2008-03-04 Bristol-Myers Squibb Company Compounds useful as motilin agonists and method
FR2866884B1 (fr) * 2004-02-26 2007-08-31 Sanofi Synthelabo Derives d'aryl-et d'heteroaryl-piperidinecarboxylates, leur preparation et leur application en therapeutique
WO2005097760A1 (en) 2004-03-26 2005-10-20 Rigel Pharmaceuticals, Inc. Heterocyclic anti-viral compounds comprising metabolizable moieties and their uses
CA2563123A1 (en) * 2004-04-02 2005-10-20 Adenosine Therapeutics, Llc Selective antagonists of a2a adenosine receptors
GB0503646D0 (en) * 2005-02-22 2005-03-30 Novartis Ag Organic compounds
AU2006228957A1 (en) * 2005-04-01 2006-10-05 Methylgene Inc. Inhibitors of histone deacetylase
GB0514296D0 (en) * 2005-07-12 2005-08-17 Novartis Ag Organic compounds
US8334290B2 (en) * 2005-10-31 2012-12-18 Merck Sharp & Dohme Corp. CETP inhibitors
KR101495611B1 (ko) * 2006-04-07 2015-02-25 메틸진 인코포레이티드 히스톤 데아세틸라아제의 억제제
US7985754B2 (en) 2006-07-17 2011-07-26 Trovis Pharmaceuticals, Llc Selective antagonists of A2A adenosine receptors

Also Published As

Publication number Publication date
DK2178858T3 (da) 2012-03-19
EP2178858A1 (en) 2010-04-28
JP2010535165A (ja) 2010-11-18
CY1112500T1 (el) 2015-12-09
WO2009015897A1 (en) 2009-02-05
NZ582934A (en) 2011-10-28
BRPI0814182A2 (pt) 2015-01-27
EA201000283A1 (ru) 2010-06-30
ES2380165T3 (es) 2012-05-09
RS52167B (sr) 2012-08-31
AU2008282032A1 (en) 2009-02-05
ATE539075T1 (de) 2012-01-15
CA2694359A1 (en) 2009-02-05
HK1141788A1 (en) 2010-11-19
ZA201001467B (en) 2010-11-24
EA018328B1 (ru) 2013-07-30
US20090042841A1 (en) 2009-02-12
CN101821256A (zh) 2010-09-01
EP2178858B1 (en) 2011-12-28
KR20100052507A (ko) 2010-05-19
US8518916B2 (en) 2013-08-27
HRP20120225T1 (hr) 2012-04-30
SI2178858T1 (sl) 2012-03-30
IL203659A (en) 2013-06-27
AU2008282032B2 (en) 2014-08-07
PT2178858E (pt) 2012-02-24
PL2178858T3 (pl) 2012-07-31

Similar Documents

Publication Publication Date Title
JP5412430B2 (ja) ｍＧｌｕ５拮抗薬としての新規複素環系化合物
JP3989444B2 (ja) 新規な化合物
JP5608655B2 (ja) Ｐ２ｘ３受容体活性のモジュレーター
TWI417100B (zh) 二唑衍生物及其作為代謝型麩胺酸受體增效劑-８４２之用途
US9062033B2 (en) Chemical compounds
JP2021522253A (ja) 化合物及びその使用
JP2007525482A (ja) イオンチャネルリガンドとしてのアミド化合物およびその使用
US20160194311A1 (en) Substituted nicotinamide derivatives as kinase inhibitors
JP6452703B2 (ja) Ｗｎｔ経路モジュレーター
PT1765795E (pt) Derivados alcinilo como moduladores de receptores metabotrópicos de glutamato
CN102123987A (zh) 亚环烷基和亚杂环烷基组蛋白脱乙酰酶抑制剂化合物
KR101851140B1 (ko) 알파 7 nAChR의 알로스테릭 조절자로서의 (피리딘-4-일)벤질아미드
TW200815351A (en) Novel compounds
KR20200013718A (ko) 바닌 억제제로서의 헤테로방향족 화합물
TR201907763T4 (tr) Ror-gama-t modülatörleri olarak triflorometil alkoller.
JP2004512323A (ja) Ｃｃｒ５ケモカイン受容体活性のピロリジンモジュレーター
JP2013529673A (ja) Ｍｇｌｕ５アンタゴニストとしての新規スピロ複素環化合物
US20120028931A1 (en) Heterocyclic m-glu5 antagonists
US20100317630A1 (en) Novel heterocyclic compounds as mglu5 antagonists
WO2006004142A1 (ja) ビアリール誘導体
HK1141788B (en) Novel heterocyclic compounds as mglu5 antagonists
WO2022028556A1 (zh) Cdk9抑制剂及其用途
WO2006115134A1 (ja) 新規なベンゾフラン誘導体、それを含有する医薬組成物およびそれらの用途
MXPA06004271A (en) Derivatives of n-[heteroaryl(piperidine-2-yl)methyl]benzamide, preparation method thereof and application of same in therapeutics

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110801

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111110

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130618

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20130620

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130918

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20131015

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20131111

LAPS Cancellation because of no payment of annual fees